Abstracts tagged "Systemic JIA and risk"

Abstract Number: 2697 • 2019 ACR/ARP Annual Meeting
Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis
Simone Carbogno ¹, Denise Pires Marafon ², Giulia Marucci ³, Manuela Pardeo ³, Antonella Insalaco ³, Virginia Messia ³, Emanuela Sacco ⁴, Ferhat Demir ⁵, Betul Sozeri ⁵, Natasia Čekada ⁶, Marija Jelusic ⁷, Olga Vougiouka ⁸, Mikhail Kostik ⁹, Alenka Gagro ¹⁰, Christoph Kessel ¹¹, Francesca Minoia ¹², Fabrizio De Benedetti ¹³ and Claudia Bracaglia¹⁴, ¹Pediatric Area, University of Milan, Milan, Italy, Milan, Italy, ²Fondazione IRCCS Ca' Grande Ospedale Maggiore Policlinico, Milan, Italy, Milan, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, ⁵University of Health Sciences , Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ⁶Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, Zagreb, Croatia, ⁷University of Zagreb, Zagreb, Croatia, ⁸P. & A. Kyriakou Children’s Hospital, Athens, Greece, Athens, Greece, ⁹Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, Saint Petersburg, Russia, ¹⁰Children's Hospital Zagreb, Zagreb, Croatia, Zagreb, Croatia, ¹¹University Hospital Muenster, Muenster, Germany, ¹²Clinica De Marchi Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, ¹³Bambino Gesù Children’s Hospital, Rome, Italy, ¹⁴Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].